From global vaccines to personalized cancer therapies, mRNA is being considered for a variety of clinical applications, creating varying requirements for production scale and dosage. To meet these diverse needs, flexibility in the manufacturing process is critical, as drug developers must determine how to efficiently deliver high yields of quality mRNA while also balancing logistical and financial goals.
Partnering with an adaptable and collaborative CDMO can be essential to navigating industry challenges and finding the best solution to bring your unique mRNA vaccine or therapeutic to market. In our upcoming webinar, we will explore different options within a standard mRNA/LNP manufacturing workflow and highlight Thermo Fisher Scientific innovations to support varying production strategies and enhance your process, including:
Register for free to get video access
Chiara Bruckmann, Ph.D.
Head of mRNA Process and Analytical Development
Chiara Bruckmann is currently Thermo Fisher Scientific’s Head of mRNA Process and Analytical Development at our manufacturing facility in Monza, Italy. With a MS in Biochemistry from University of Rome and Ph.D. in Structural Biology and Chemistry from the University of Edinburgh, Chiara brings more than 15 years of experience in translational research and R&D. She has expertise in Biochemistry, Molecular Biology, Biophysics and Cell Biology, as well as extensive experience in downstream processes and developing analytical tools and techniques to understand complex protein-nucleic acid systems. Prior to joining Thermo Fisher Scientific, she worked in the R&D pre-clinical division of small Italian biotech and contributed to moving the company’s lead candidate into the clinical phase.
Sean Essex, Ph.D.
Global Subject Matter Expert, mRNA & LNP
Sean Essex is currently Thermo Fisher Scientific’s Global Subject Matter Expert (SME) for mRNA/LNP. In this role, he serves as the scientific advisor for commercial operations for mRNA, provides technical design for mRNA programs, and supports clients and on-site operations. Sean brings 11+ years of biotech/pharma industry experience, with past scientific and leadership roles primarily focused on R&D and CMC at Life Technologies, Poseida Therapeutics, Oncorus, and Arcturus Therapeutics. His area of expertise includes employing design of experiment (DOE) principles into scientific workflows to solve complex problems in an efficient manner. Sean holds MS and Ph.D. degrees in pharmaceutical sciences from Northeastern University with a focus on novel drug delivery systems.